Abnormal hepatic apolipoprotein B metabolism in type 2 diabetes.
Level 5 - mechanism / opinion, no new human data
Narrative review of pathophysiological mechanisms without original human data or systematic review methodology
PubMed 20189175 · doi:10.1016/j.atherosclerosis.2010.01.028
What was done
This paper is a narrative review synthesizing pathophysiological mechanisms underlying abnormal hepatic apolipoprotein B (apoB) and very low-density lipoprotein (VLDL) metabolism in type 2 diabetes. The abstract describes cellular pathways; it does not report primary patient data, experimental trials, or a systematic search strategy.
What was found
No quantitative data or effect sizes are reported in the abstract. It describes qualitative mechanistic pathways contributing to increased hepatic VLDL1 particle production: - Insulin resistance impairs hepatocyte PI3-kinase activation, leading to reduced apoB degradation, increased microsomal triglyceride transfer protein (MTP) expression via FoxO1 and Foxa2, and increased phospholipase D1 and ARF-1 activity. - Peripheral adipose insulin resistance elevates lipolysis, increasing portal free fatty acid (FFA) delivery to the liver. - Hepatic de novo lipogenesis is augmented through endoplasmic reticulum stress-mediated SREBP-1c activation and hyperglycemia-mediated ChREBP activation. - Decreased adiponectin levels impair hepatic AMP-kinase activation and muscle FFA oxidation, further raising circulating FFAs.
Why it matters
It outlines how hepatic and peripheral insulin resistance drive the overproduction of VLDL1 particles, generating atherogenic remnants, small dense LDL, and triglyceride-rich HDL in diabetic dyslipidemia.
Limits
The abstract provides no empirical numbers, sample sizes, or clinical outcomes. As a narrative review, it offers mechanistic-level reasoning without systematic study selection or risk-of-bias evaluation.
Cited by
- supports High-carbohydrate diets promote hepatic VLDL particle production that leads to the atherogenic dyslipidemia phenotype: elevated triglycerides, increased small LDL, and lower HDL.